BIOV Stock Overview
BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BioVaxys Technology Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.075 |
| 52 Week High | CA$0.10 |
| 52 Week Low | CA$0.01 |
| Beta | 0.12 |
| 1 Month Change | 0% |
| 3 Month Change | 66.67% |
| 1 Year Change | 50.00% |
| 3 Year Change | -76.92% |
| 5 Year Change | n/a |
| Change since IPO | -80.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOV | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -6.3% | -9.9% | -3.0% |
| 1Y | 50.0% | 46.0% | 3.2% |
Return vs Industry: BIOV exceeded the Canadian Pharmaceuticals industry which returned 44.4% over the past year.
Return vs Market: BIOV exceeded the Canadian Market which returned 3.9% over the past year.
Price Volatility
| BIOV volatility | |
|---|---|
| BIOV Average Weekly Movement | 25.1% |
| Pharmaceuticals Industry Average Movement | 14.1% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: BIOV's share price has been volatile over the past 3 months.
Volatility Over Time: BIOV's weekly volatility has decreased from 32% to 25% over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Chris Passin | biovaxys.com |
BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms. It develops BVX-0320, a SARS-CoV-2 vaccine; BVX-1021, a vaccine for the strain of coronavirus that causes SARS1; and BVX-0918, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, a novel diagnostic platform to identify a T-cell immune response to the presence of SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions.
BioVaxys Technology Corp. Fundamentals Summary
| BIOV fundamental statistics | |
|---|---|
| Market cap | CA$16.87m |
| Earnings (TTM) | -CA$12.57m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs BIOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOV income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$12.57m |
| Earnings | -CA$12.57m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BIOV perform over the long term?
See historical performance and comparison